Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. Eli Lilly (NYSE: LLY) has been on fire over the past ...

In one of the first major tests of the new FDA leadership’s regulatory philosophy toward gene therapies for rare diseases, ...

Becker’s asked pharmacy executives from hospitals and health systems across the U.S. to share what their system has done to expand their access to care. The 10 executives featured in this article are ...

The biggest downside of this new treatment is that all participants will need to take immunosuppressant drugs for the rest of their lives. This will reduce the immune system’s ability to recognise the ...

The cure for diabetes is a life free from daily insulin injections. Based on that criterion, ten out of 12 people (83%) in a new clinical trial were ...